The potential mechanism of Isodon suzhouensis against COVID-19 via EGFR/TLR4 pathways

扫码查看

原文链接

万方数据

外文摘要：Corona Virus Disease 2019(COVID-19)has brought the new challenges to scientific research.Isodon suzhouensis has good anti-inflammatory and antioxidant stress effects,which is considered as a potential treatment for COVID-19.The possibility for the treatment of COVID-19 with I.suzhouensis and its potential mechanism of action were explored by employing molecular docking and network pharmacology.Network pharmacology and molecular docking were used to screen drug targets,and lipopolysaccharide(LPS)induced RAW264.7 and NR8383 cells inflammation model was used for experimental verification.Collectively a total of 209 possible linkages against 18 chemical components from I.suzhouensis and 1 194 COVID-19 related targets were selected.Among these,164 common targets were obtained from the intersection of I.suzhouensis and COVID-19.Gene Ontology(GO)and Kyoto Encyclopedia of Genes and Genomes(KEGG)enriched 582 function targets and 87 target proteins pathways,respectively.The results from molecular docking studies revealed that rutin,vitexin,isoquercitrin and quercetin had significant binding ability with 3 chymotrypsin like protease(3CLpro)and angiotensin converting enzyme 2(ACE2).In vitro studies showed that I.suzhouensis extract(ISE)may inhibit the activation of PI3K/Akt pathway and the expression level of downstream pro-inflammatory factors by inhibiting the activation of epidermal growth factor receptor(EGFR)in RAW264.7 cells induced by LPS.In addition,ISE was able to inhibit the activation of TLR4/NF-κB signaling pathway in NR8383 cells exposed to LPS.Overall,the network pharmacology and in vitro studies conclude that active components from I.suzhouensis have strong therapeutic potential against COVID-19 through multi-target,multi-pathway dimensions and can be a promising candidate against COVID-19.

外文关键词：

Isodon suzhouensisCOVID-19Network pharmacologyTLR4/NF-κB pathwayEpidermal growth factor receptorPI3K/Akt pathway

作者：

Hong Duan、Wei Wang、Shu Li、Han Li、Ghulam Jilany Khan、Yong Ma、Fawang Liu、Kefeng Zhai、Henggui Hu、Zhaojun Wei

展开 >

作者单位：

School of Biological and Food Engineering,Engineering Research Center for Development and High Value Utilization of Genuine Medicinal Materials in North Anhui Province,Suzhou University,Suzhou 234000,China

College of Biological and Food Engineering,Anhui Polytechnic University,Wuhu 241000,China

Department of Pharmacology and Therapeutics,Faculty of Pharmacy,University of Central Punjab,Lahore 54000,Pakistan

Suzhou YiFan Pharmaceutical Co.,Ltd.,Suzhou 234000,China

General Clinical Research Center,Anhui Wanbei Coal-Electricity Group General Hospital,Suzhou 234000,China

School of Biological Science and Engineering,North Minzu University,Yinchuan 750021,China

展开 >

出版年：

2024

DOI：

10.26599/FSHW.2023.9250011

食品科学与人类健康(英文)

CSTPCD

ISSN：

年,卷(期)：2024.13(6)